share_log

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

aclaris therapeutics将参加派杰投资第36届年度医疗保健大会
GlobeNewswire ·  11/27 05:30

WAYNE, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 1:00 PM ET in New York, New York.

宾夕法尼亚州韦恩,2024年11月26日(环球新闻通讯)—— aclaris therapeutics, inc.(纳斯达克:ACRS),一家专注于开发用于免疫炎症疾病的新型药物候选的临床阶段生物制药公司,今天宣布,aclaris管理团队的成员将参加于2024年12月3日下午1:00(东部时间)在纽约市举行的派杰投资第36届年度医疗保健会议的炉边聊天。

A webcast of the fireside chat may be accessed through the "Events" page of the "Investors" section of Aclaris' website, . The webcast will be archived for at least 30 days on the Aclaris website.

通过Aclaris官网的“投资者”版块的“活动”页面,可以访问座谈会的网络直播。该网络直播将在Aclaris官网存档至少30天。

About Aclaris Therapeutics, Inc.

关于Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit .

Aclaris Therapeutics, Inc.是一家临床阶段的生物制药公司,致力于开发一系列新型药物候选品,以满足免疫炎症性疾病患者的需求,这些患者缺乏满意的治疗选择。该公司拥有一个多阶段的药物候选品组合,由强大的研发引擎驱动,探索蛋白激酶调控。更多信息请访问。

Aclaris Therapeutics Contact:

Aclaris Therapeutics 联系方式:

investors@aclaristx.com

investors@aclaristx.com


声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发